Removing clots during angioplasty to open up a blocked coronary artery has become a common practice. This study of a large number of randomly selected patients showed that there was little difference between those patients who had only angioplasty and those who had angioplasty and manual removal of blood clots with respect to major cardiac problems (cardiovascular death, recurrent heart attack, cardiac shock, or heart failure) in the six-months after treatment. Both outcomes were essentially the same. However, there was an increase in strokes in the 30 days after treatment in patients who had their clots manually removed along with the angioplasty.
The story does a fine job of communicating the major findings of the study and meets the standard on most of our criteria. Apart from some discussion of cost, the main item on our wish list would be more thoughtful evaluation from an independent expert. Although an outside expert is quoted, he doesn’t do much more than affirm that the findings are important. Just how important are they and what should the patient — the target of this story — do with this information?
Angioplasty is common after a cardiac event and manual clot removal is considered routine practice. If this practice has no practical clinical value and has negative implications for strokes within 30 days after treatment, then perhaps this routine practice should be re-evaluated. Even if the increase in strokes is small, the fact that clot removal appears to have no benefit, but would take longer and incur more cost, make it appear unnecessary.
The story does not discuss the cost of angioplasty, or whether that cost would be affected if routine practice regarding clot removal is changed. While there are many ways that costs might change that would be difficult or impossible to predict (for example, the impact of differing stroke rates and the related follow-up care), it should have been possible to estimate the direct costs of the procedure with or without clot removal.
The story reports the absolute difference in the primary composite outcome in the two groups in this study (in fact there was no difference between those groups, indicating no added benefit for clot removal), which earns the story a satisfactory rating here.
With that being said, the general benefits of angioplasty are not really discussed in the story. The assumption made is that after a heart attack, where clogged arteries occur, angioplasty is an accepted and effective treatment. A bit of background on angioplasty as a treatment and stent placement might have filled out this story and made it clearer why these two approaches were being evaluated in the first place.
The story clearly states that there is no apparent benefit for clot removal and that there is some increased occurrence of strokes with the procedure. The absolute percentage of subjects who had a stroke in each group is also provided, so readers get a very clear picture of how often this occurs and the difference between the groups.
The story reports that this was a large randomized trial done by a team who has been doing research in this area. It quotes an expert who says that this has been an “eagerly awaited trial” that “will likely have important implications for clinical practice.” So there’s enough information here to discern that this was a well-conducted study that produced meaningful results, and we’ll award the story a Satisfactory rating on that basis. However, we wish the story had pushed just a bit harder as to what the “important implications” of this study will likely be. It seems that there’s a lot of conflicting data in this area, and it’s not clear from the story how the results may change practice — and that’s perspective that readers would like to have.
There was no disease mongering in this story. Heart attacks occur and need to be treated, and this story presents a view on what the best treatment might be.
The information was released simultaneously in the New England Journal of Medicine and presented at a conference. The story references data from the study and quotes an expert who was not affiliated with the study. While the story meets our standard, we wish that the independent expert had been pressed for a more meaningful evaluation, as discussed above.
The alternative here is clearly to do the angioplasty without clot removal. That is satisfactorily established. We wish the story had been a bit clearer about the different techniques available for clot removal, however. The story talks about “manual” vs. “mechanical” removal, but never explains what that means. The press release notes that with “manual” clot removal,”the surgeon uses a syringe to create suction to remove clots,” whereas mechanical removal “uses machinery to create the suction.”
The story does not mention the availability of either of these procedures, but assumes that both are readily available and widespread. That’s accurate.
The story makes clear that there was prior research on this topic showing benefit from clot removal.
While there is a press release on this study produced by the conference, the expert interviews are evidence that the story did not rely on them excessively. We’d note that there is some information in the press release that would have made the story better.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like